Clinical Trials Browser

Carcinoma, Non-Small-Cell Lung × Injections × 1 year × Clear all

NCT04908111 2026-04-06

A Trial of ChAdOx1 and MVA Vaccines Against MAGE-A3 and NY-ESO-1

Phase 1/2 Suspended

GastrointestinalThoracic

Carcinoma, Non-Small-Cell Lung, Esophageal Neoplasms, Lung Neoplasms, Neoplasms, Neoplasms, Squamous Cell

NCT06956001 2026-02-12

Firmonertinib Versus Platinum Based Chemotherapy as First-line Treatment for NSCLC With EGFR PACC or EGFR l861q Mutation

Phase 3 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT07230405 2026-02-06

A Phase II Study of SKB571 in Patients With Lung Cancer

Phase 2 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT04081688 2026-02-05

Atezolizumab and Varlilumab in Combination With Radiation Therapy for NSCLC

Phase 1 Terminated

16 enrolled 9 charts

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT05816252 2026-01-27

MK-2870-003

Phase 2 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT07348211 2026-01-23

SIM0610-101

Phase 1 Recruiting

GastrointestinalHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Hepatocellular, Colorectal Neoplasms

NCT06903377 2026-01-05

Study of ZG005 Combined With Gecacitinib in Patients With Advanced Non-Small Cell Lung Cancer

Phase 1/2 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT06512051 2025-12-23

A Trial of SHR-A2102 With Adebrelimab With or Without Other Antitumor Therapy in Advanced or Metastatic Non-small Cell Lung Cancer

Phase 1/2 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT06496490 2025-11-20

A Clinical Trial of TQB2102 for Injection in Non-small Cell Lung Cancer With HER2 Gene Abnormality

Phase 2 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT07169994 2025-09-12

A Study of YL202 in Combination With Other Anti-tumor Therapies in Patients With Advanced Solid Tumors

Phase 1/2 Recruiting

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung

NCT04778839 2025-08-06

Study of Paclitaxel Micelles for Injection in Chinese Patients With Advanced Solid Tumors.

Phase 1 Recruiting

BreastGastrointestinalGynecologicThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Ovarian Neoplasms, Stomach Neoplasms

NCT06962865 2025-07-16

A Phase Ⅱ Study of RC108 in Combination With Furmonertinib for the First-line Treatment of EGFR-Mutated Combined MET-Positive Unresectable Locally Advanced or Recurrent Metastatic NSCLC

Phase 2 Recruiting

Carcinoma, Non-Small-Cell Lung